Reduced cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with low b-value diffusion weighted imaging
- PMID: 38725029
- PMCID: PMC11080257
- DOI: 10.1186/s12987-024-00542-8
Reduced cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with low b-value diffusion weighted imaging
Abstract
Background: Parkinson's disease is characterized by dopamine-responsive symptoms as well as aggregation of α-synuclein protofibrils. New diagnostic methods assess α-synuclein aggregation characteristics from cerebrospinal fluid (CSF) and recent pathophysiologic mechanisms suggest that CSF circulation disruptions may precipitate α-synuclein retention. Here, diffusion-weighted MRI with low-to-intermediate diffusion-weightings was applied to test the hypothesis that CSF motion is reduced in Parkinson's disease relative to healthy participants.
Methods: Multi-shell diffusion weighted MRI (spatial resolution = 1.8 × 1.8 × 4.0 mm) with low-to-intermediate diffusion weightings (b-values = 0, 50, 100, 200, 300, 700, and 1000 s/mm2) was applied over the approximate kinetic range of suprasellar cistern fluid motion at 3 Tesla in Parkinson's disease (n = 27; age = 66 ± 6.7 years) and non-Parkinson's control (n = 32; age = 68 ± 8.9 years) participants. Wilcoxon rank-sum tests were applied to test the primary hypothesis that the noise floor-corrected decay rate of CSF signal as a function of b-value, which reflects increasing fluid motion, is reduced within the suprasellar cistern of persons with versus without Parkinson's disease and inversely relates to choroid plexus activity assessed from perfusion-weighted MRI (significance-criteria: p < 0.05).
Results: Consistent with the primary hypothesis, CSF decay rates were higher in healthy (D = 0.00673 ± 0.00213 mm2/s) relative to Parkinson's disease (D = 0.00517 ± 0.00110 mm2/s) participants. This finding was preserved after controlling for age and sex and was observed in the posterior region of the suprasellar cistern (p < 0.001). An inverse correlation between choroid plexus perfusion and decay rate in the voxels within the suprasellar cistern (Spearman's-r=-0.312; p = 0.019) was observed.
Conclusions: Multi-shell diffusion MRI was applied to identify reduced CSF motion at the level of the suprasellar cistern in adults with versus without Parkinson's disease; the strengths and limitations of this methodology are discussed in the context of the growing literature on CSF flow.
Keywords: Cerebrospinal fluid; Choroid plexus; DWI; Glymphatic; Parkinson’s; Suprasellar cistern; α-synuclein.
© 2024. The Author(s).
Conflict of interest statement
No authors declare any relevant conflicts or disclosures regarding the work presented in this manuscript. Manus J. Donahue receives research related support from the National Institutes of Health (NINDS, NCI, NIA, NCCIH, NINR, and NHLBI), Philips Healthcare and is a paid consultant for Graphite Bio, Pfizer Inc, Global Blood Therapeutics, and LymphaTouch. He is a paid advisory board member for Novartis and bluebird bio and receives research funding from the National Institutes of Health and Pfizer Inc. Manus J. Donahue is also the CEO of Biosight Inc which operates as a clinical research organization and provides healthcare technology vendor services. Ciaran Considine?s financial disclosures include those associated with his private consulting practice, NeuropsyConsulting LLC, i.e., Forensic Consulting with Park Dietz & Associates, clinical-research advisory panel member with MDisrupt, external advisory board for HD Genetics. He also receives academic-research grant support from the NIH, NIA, and DoD, and acts as PI on an investigator-initiated clinical study funded by Acadia. Daniel O. Claassen has received research support from the NIH/NINDS/NIA/NICHD/NCCIH, Department of Defense, Griffin Family Foundation, and Huntington Disease Society of America; he has received pharmaceutical grant support from AbbVie, Alterity, Acadia, Biogen, BMS, Cerecour, Eli Lilly, Genentech-Roche, Lundbeck, Jazz Pharmaceuticals, Neurocrine, Teva Neuroscience, Wave Life Sciences, UniQure, and Vaccinex. He has received personal fees for consulting from Acadia, Alterity, Adamas, Anexon, Ceruvel, Lundbeck, Neurocrine, Spark, Uniqure, and Teva Neuroscience.
Figures






Update of
-
Reduced suprasellar cistern cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with dynamic cycling of diffusion weightings.Res Sq [Preprint]. 2023 Sep 7:rs.3.rs-3311121. doi: 10.21203/rs.3.rs-3311121/v1. Res Sq. 2023. Update in: Fluids Barriers CNS. 2024 May 9;21(1):40. doi: 10.1186/s12987-024-00542-8. PMID: 37720044 Free PMC article. Updated. Preprint.
Similar articles
-
Reduced suprasellar cistern cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with dynamic cycling of diffusion weightings.Res Sq [Preprint]. 2023 Sep 7:rs.3.rs-3311121. doi: 10.21203/rs.3.rs-3311121/v1. Res Sq. 2023. Update in: Fluids Barriers CNS. 2024 May 9;21(1):40. doi: 10.1186/s12987-024-00542-8. PMID: 37720044 Free PMC article. Updated. Preprint.
-
Diffusion analysis of fluid dynamics with incremental strength of motion proving gradient (DANDYISM) to evaluate cerebrospinal fluid dynamics.Jpn J Radiol. 2021 Apr;39(4):315-323. doi: 10.1007/s11604-020-01075-4. Epub 2021 Jan 2. Jpn J Radiol. 2021. PMID: 33389526 Free PMC article.
-
Feasibility of Diffusion-weighted Imaging (DWI) for Assessing Cerebrospinal Fluid Dynamics: DWI-fluidography in the Brains of Healthy Subjects.Magn Reson Med Sci. 2025 Apr 1;24(2):166-175. doi: 10.2463/mrms.mp.2022-0152. Epub 2024 Feb 14. Magn Reson Med Sci. 2025. PMID: 38355106 Free PMC article.
-
Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.Parkinsonism Relat Disord. 2019 Feb;59:21-25. doi: 10.1016/j.parkreldis.2018.11.016. Epub 2018 Nov 15. Parkinsonism Relat Disord. 2019. PMID: 30466800 Review.
-
Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.J Neurochem. 2016 Oct;139 Suppl 1:290-317. doi: 10.1111/jnc.13390. Epub 2016 Feb 10. J Neurochem. 2016. PMID: 26452984 Review.
Cited by
-
Microglial dynamics and neuroinflammation in prodromal and early Parkinson's disease.J Neuroinflammation. 2025 May 21;22(1):136. doi: 10.1186/s12974-025-03462-y. J Neuroinflammation. 2025. PMID: 40399949 Free PMC article. Review.
-
Functional abnormalities of the glymphatic system in cognitive disorders.Neural Regen Res. 2025 Dec 1;20(12):3430-3447. doi: 10.4103/NRR.NRR-D-24-01049. Epub 2025 Jan 13. Neural Regen Res. 2025. PMID: 39820293 Free PMC article.
-
Diffusion Tensor Imaging in Neurofluids.Neuroimaging Clin N Am. 2025 May;35(2):211-222. doi: 10.1016/j.nic.2024.11.001. Epub 2025 Feb 21. Neuroimaging Clin N Am. 2025. PMID: 40210378 Review.
-
Alpha-synuclein pathology and Parkinson's disease-related olfactory dysfunctions: an update on preclinical models and therapeutic approaches.Mamm Genome. 2025 Jun;36(2):444-464. doi: 10.1007/s00335-025-10128-w. Epub 2025 Apr 28. Mamm Genome. 2025. PMID: 40293510 Free PMC article. Review.
-
Targeting the glymphatic system to promote α-synuclein clearance: a novel therapeutic strategy for Parkinson's disease.Neural Regen Res. 2026 Jan 1;21(1):233-247. doi: 10.4103/NRR.NRR-D-24-00764. Epub 2025 Jan 13. Neural Regen Res. 2026. PMID: 39819820 Free PMC article.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials